Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,055,897 papers from all fields of science
Search
Sign In
Create Free Account
AH 13205
Known as:
AH-13205
, AH13205
, Cyclopentaneheptanoic acid, 2-(4-(1-hydroxyhexyl)phenyl)-5-oxo-
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Prostanoic Acids
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
EP4 Receptor Agonists: The Most Promising Novel Bronchodilator For Several Decades
James F Buckley
,
M. Birrell
,
Sarah A. Maher
,
D. Clarke
,
A. Nials
,
M. Belvisi
Asian Test Symposium
2011
Corpus ID: 55758635
Due to recent safety concerns with beta 2 adrenoceptor agonists (e.g. salbutamol), there has been an ongoing attempt to identify…
Expand
2010
2010
C 025 EP 4 receptor agonists : the most promising novel bronchodilator for several decades
James F Buckley
,
M. Birrell
,
Sarah A. Maher
,
A. Nials
,
D. Clarke
,
M. Belvisi
2010
Corpus ID: 13872558
Due to recent safety concerns with beta 2 adrenoceptor agonists (e.g. salbutamol), there has been an ongoing attempt to identify…
Expand
1997
1997
Prostaglandin effects on the contractility of bovine trabecular meshwork and ciliary muscle.
A. Krauss
,
M. Wiederholt
,
A. Sturm
,
D. Woodward
Experimental Eye Research
1997
Corpus ID: 22309365
The ocular hypotensive activity of prostaglandins (PGs) has previously been demonstrated in various species including man. The…
Expand
1994
1994
Characterization of the prostaglandin E2 sensitive (EP)‐receptor in the rat isolated trachea
S. Lydford
,
K. McKechnie
British Journal of Pharmacology
1994
Corpus ID: 40776431
1 Using a range of natural and synthetic prostanoid receptor agonists and antagonists, we have shown that the rat isolated…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE